Tags

Type your tag names separated by a space and hit enter

Identification of a basal-like subtype of breast ductal carcinoma in situ.
Hum Pathol. 2007 Feb; 38(2):197-204.HP

Abstract

Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The aim of this study was to determine the prevalence of basal-like ductal carcinoma in situ in a population-based series of cases using immunohistochemical surrogates. A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. The subtypes were defined as: luminal A (ER+, HER2-), luminal B (ER+, HER2+), HER2 positive (ER-, HER2+), and basal-like (ER-, HER2-, EGFR+, and/or cytokeratin 5/6+). The prevalence of breast cancer subtypes was basal-like (n = 19 [8%]); luminal A, n = 149 (61%); luminal B, n = 23 (9%); and HER2+/ER-, n = 38 (16%). Sixteen tumors (6%) were unclassified (negative for all 4 defining markers). The basal-like subtype was associated with unfavorable prognostic variables including high-grade nuclei (P < .0001), p53 overexpression (P < .0001), and elevated Ki-67 index (P < .0001). These studies demonstrate the presence of a basal-like in situ carcinoma, a potential precursor lesion to invasive basal-like carcinoma.

Authors+Show Affiliations

Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA. cal@med.unc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17234468

Citation

Livasy, Chad A., et al. "Identification of a Basal-like Subtype of Breast Ductal Carcinoma in Situ." Human Pathology, vol. 38, no. 2, 2007, pp. 197-204.
Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197-204.
Livasy, C. A., Perou, C. M., Karaca, G., Cowan, D. W., Maia, D., Jackson, S., Tse, C. K., Nyante, S., & Millikan, R. C. (2007). Identification of a basal-like subtype of breast ductal carcinoma in situ. Human Pathology, 38(2), 197-204.
Livasy CA, et al. Identification of a Basal-like Subtype of Breast Ductal Carcinoma in Situ. Hum Pathol. 2007;38(2):197-204. PubMed PMID: 17234468.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of a basal-like subtype of breast ductal carcinoma in situ. AU - Livasy,Chad A, AU - Perou,Charles M, AU - Karaca,Gamze, AU - Cowan,David W, AU - Maia,Diane, AU - Jackson,Susan, AU - Tse,Chiu-Kit, AU - Nyante,Sarah, AU - Millikan,Robert C, PY - 2006/07/07/received PY - 2006/08/23/revised PY - 2006/08/24/accepted PY - 2007/1/20/pubmed PY - 2007/3/9/medline PY - 2007/1/20/entrez SP - 197 EP - 204 JF - Human pathology JO - Hum Pathol VL - 38 IS - 2 N2 - Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The aim of this study was to determine the prevalence of basal-like ductal carcinoma in situ in a population-based series of cases using immunohistochemical surrogates. A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. The subtypes were defined as: luminal A (ER+, HER2-), luminal B (ER+, HER2+), HER2 positive (ER-, HER2+), and basal-like (ER-, HER2-, EGFR+, and/or cytokeratin 5/6+). The prevalence of breast cancer subtypes was basal-like (n = 19 [8%]); luminal A, n = 149 (61%); luminal B, n = 23 (9%); and HER2+/ER-, n = 38 (16%). Sixteen tumors (6%) were unclassified (negative for all 4 defining markers). The basal-like subtype was associated with unfavorable prognostic variables including high-grade nuclei (P < .0001), p53 overexpression (P < .0001), and elevated Ki-67 index (P < .0001). These studies demonstrate the presence of a basal-like in situ carcinoma, a potential precursor lesion to invasive basal-like carcinoma. SN - 0046-8177 UR - https://www.unboundmedicine.com/medline/citation/17234468/Identification_of_a_basal_like_subtype_of_breast_ductal_carcinoma_in_situ_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0046-8177(06)00534-X DB - PRIME DP - Unbound Medicine ER -